Figure 1.
Flow diagram of literature search and selection process.
Abbreviations: PD = Parkinson’s disease; RCT = Randomized controlled trial.
Table 1.
The main characteristics of the included randomized controlled trails.
Figure 2.
Impact of rotigotine versus placebo on UPDRS scores.
Panel A: UPDRS ADL score. Panel B: UPDRS motor score. Panel C: UPDRS ADL and motor subtotal score. Abbreviations: UPDRS = unified Parkinson’s disease rating scale; ADL = activities of daily living.
Table 2.
Efficacy and tolerability results of overall and subgroup analyses.
Figure 3.
Effect of rotigotine versus placebo on withdrawals.
Panel A: Overall withdrawals. Panel B: Withdrawals due to adverse events.
Figure 4.
The pooled incidence of adverse events in PD patients treated with rotigotine.
Abbreviations: ASR = Application site reactions; LD = levodopa.
Table 3.
Safety results of overall and subgroup analyses.
Figure 5.
Effect of rotigotine versus placebo on the incidence of adverse events.
Panel A: Application site reactions. Panel B: Dizziness. Panel C: Headache. Panel D: Serious adverse events.